Effects of clofutriben, a selective 11β-hydroxysteroid dehydrogenase type 1 inhibitor, on the efficacy and toxicity of prednisolone in patients with polymyalgia rheumatica: a single-blind controlled trial with sequential cohorts
Further trials to assess clofutriben's potential to improve the benefit-risk profile of prednisolone are warranted.
Authors
- Frank S. Czerwiec
- Ioana Andreica (ORCID: https://orcid.org/0000-0002-8007-9905)
- Andrea Everding
- Paul M. Stewart (ORCID: https://orcid.org/0000-0002-1749-9640)
- Cornelia M. Weyand (ORCID: https://orcid.org/0000-0003-2230-9802)
- Frank Buttgereit (ORCID: https://orcid.org/0000-0003-2534-550X)
- Ketan Desai
- Florian Schuch (ORCID: https://orcid.org/0000-0002-2543-0491)
- Christian Dejaco (ORCID: https://orcid.org/0000-0002-0173-0668)
- David A. Katz (ORCID: https://orcid.org/0000-0002-4400-5669)
- Peter A. Merkel (ORCID: https://orcid.org/0000-0001-9284-7345)
- H Kellner
Institutions
- University of Leeds (GB)
- Mayo Clinic (US)
- Medical University of Graz (AT)
- Sparrow Hospital (US)
- Universitätsklinikum Erlangen (DE)
- Rheumazentrum Ruhrgebiet (DE)
- München Klinik (DE)
- Charité - Universitätsmedizin Berlin (DE)
- University of Pennsylvania (US)
Publication Details
- Journal
- Annals of the Rheumatic Diseases
- Published
- 2025-11-01
- DOI
- https://doi.org/10.1016/j.ard.2025.10.015
- Primary Topic
- Vasculitis and related conditions
- Type
- article
- Field-Weighted Citation Impact
- 0.00